ABAllison L. Bayer

Allison L. Bayer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Allison L. Bayer has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Evaluation of Computationally Designed IL-10 in IL-10 KO Mice

    by Jordan Stokes, Iram Hyder, Zhihang Shen, Peter Ramdhan, Allison Bayer, Clive Wasserfall, Chenglong Li, Sihong Song

    Studies have shown that IL-10 has therapeutic potential for inflammatory diseases. However, it is challenging to use IL-10 as a therapeutic drug because it also possesses pro-inflammatory functions. To reduce these pro-inflammatory effects of IL-10, we have designed three IL-10 mutants using structure-based computational design technology. We demonstrated that these mutants exhibited significantly lower activity in IL-10-responsive cell lines than wild-type IL-10. Using recombinant adeno-associated virus (rAAV8) vectors expressing wild-type or mutant IL-10 molecules, we performed gene therapy experiments in IL-10 KO mice. The results showed that our vectors mediated high levels of transgene expression. Importantly, IL-10 gene therapy increased body weight gain, reduced colon injury, and prevented the development of inflammatory bowel disease (IBD). Moreover, IL-10 mutant gene therapy elicited significantly lower stimulation of CD8 T and NK cells compared with the wild-type IL-10 group. In summary, our IL-10 mutants provide a protective effect comparable to wild-type IL-10 in the IL-10 KO mouse model, suggesting that they may potentially have reduced pro-inflammatory function. While rigorous investigations of safety and efficacy in different disease models will be required, these results indicate the therapeutic potential of IL-10 mutant gene therapy for inflammatory diseases such as IBD.

  • Protection Against Type 1 Diabetes Development in Mice With 4E-BP2 Deletion

    by Valentina Pita-Grisanti, Flavia Leticia Martins Peçanha, Ruy A. Louzada, Manuel Blandino-Rosano, Camillo Jaramillo, Natalia Arenas, Allison Bayer, Ernesto Bernal-Mizrachi

    Type 1 diabetes (T1D) is an autoimmune disease characterized by β-cell destruction promoted by autoreactive T cells. Eukaryotic translation initiation factor 4E (eIF4E)–binding protein 1 (4E-BP1) and 4E-BP2 are translational repressors and downstream targets of mammalian target of rapamycin complex 1 (mTORC1). Activation of the 4E-BP2/eIF4E pathway by 4E-BP2 deletion promotes translation initiation, inducing β-cell expansion and proliferation and regulating adaptive immunity. However, the involvement of 4E-BP2 in T1D remains unexplored. This study aimed to determine the role of 4E-BP2/eIF4E signaling in T1D prevention. We used the NOD mouse model of T1D and generated mice with global 4E-BP2 deletion in the NOD background (Eif4ebp2−/−). We assessed T1D development, glucose homeostasis, pancreas morphometry, and immune responses in Eif4ebp2−/− and littermate control mice. We found that Eif4ebp2−/− male mice exhibited reduced diabetes incidence, which did not occur in female mice, as well as preserved β-cell mass, improved insulin secretion in vitro, and comparable insulitis. Characterization of T-cell compartments showed decreased splenic CD8+ cytotoxic T-cell proliferation and increased pancreatic regulatory T-cell infiltration in Eif4ebp2−/− mice, potentially resulting from increased proliferation and suppressive capacity. Adoptive transfer studies demonstrated that Eif4ebp2−/− male lymphocytes were less diabetogenic than those of controls. In conclusion, activation of 4E-BP2/eIF4E by 4E-BP2 deletion protected against T1D, supporting 4E-BP2 as a potential therapy target. Article Highlights: Mammalian target of rapamycin complex 1 (mTORC1) signaling is essential to β-cell mass, function, and adaptive immunity; however, its specific downstream mediators in type 1 diabetes (T1D) remain poorly defined. We investigated eukaryotic translation initiation factor 4E–binding protein 2 (4E-BP2), a major translational regulator downstream of mTORC1, by using global 4E-BP2–knockout mice on the NOD background. Loss of 4E-BP2 protected male NOD mice from T1D through preservation of β-cell mass and function, coupled with attenuation of autoimmune responses. These findings identify 4E-BP2 as a novel immunometabolic node, highlighting its potential as a therapeutic target for T1D prevention and treatment.

  • Open Access

    Protection Against Type 1 Diabetes Development in Mice with 4E-BP2 Deletion

    by Valentina Pita-Grisanti, Flavia Leticia Martins Peçanha, Ruy A Louzada, Manuel Blandino-Rosano, Camillo Jaramillo, Natalia Arenas, Allison Bayer, Ernesto Bernal-Mizrachi

    Type 1 diabetes (T1D) is an autoimmune disease characterized by β-cell destruction promoted by autoreactive T cells. 4E-BP1/2 proteins are translational repressors and downstream targets of mTORC1. Activation of 4E-BP2/eIF4E pathway by 4E-BP2 deletion promotes translation initiation, inducing β-cell expansion and proliferation and regulating adaptive immunity. However, the involvement of 4E-BP2 in T1D remains unexplored. This study aimed to determine the role of 4E-BP2/eIF4E signaling in T1D prevention. We used the non-obese diabetic (NOD) mouse model of T1D, and generated mice with global 4E-BP2 deletion in the NOD background (Eif4epb2-/-). We assessed T1D development, glucose homeostasis, pancreas morphometry and immune responses in Eif4epb2-/- and littermate control mice. We found that Eif4epb2-/- male mice exhibited reduced diabetes incidence, which did not occur in female mice, and was associated with preserved β-cell mass, improved insulin secretion in vitro, and comparable insulitis. Characterization of T cell compartments showed decreased splenic CD8+ cytotoxic T cell proliferation and increased pancreatic regulatory T cell infiltration in Eif4epb2-/- mice, potentially due to increased proliferation and suppressive capacity. Adoptive transfer studies demonstrated that Eif4epb2-/- male lymphocytes were less diabetogenic than controls. Overall, activation of 4E-BP2/eIF4E by 4E-BP2 deletion protects against T1D, identifying 4E-BP2 as a potential therapy target.

  • Open Access

    Protection Against Type 1 Diabetes Development in Mice with 4E-BP2 Deletion

    by Valentina Pita-Grisanti, Flavia Leticia Martins Peçanha, Ruy A Louzada, Manuel Blandino-Rosano, Camillo Jaramillo, Natalia Arenas, Allison Bayer, Ernesto Bernal-Mizrachi

    Type 1 diabetes (T1D) is an autoimmune disease characterized by β-cell destruction promoted by autoreactive T cells. 4E-BP1/2 proteins are translational repressors and downstream targets of mTORC1. Activation of 4E-BP2/eIF4E pathway by 4E-BP2 deletion promotes translation initiation, inducing β-cell expansion and proliferation and regulating adaptive immunity. However, the involvement of 4E-BP2 in T1D remains unexplored. This study aimed to determine the role of 4E-BP2/eIF4E signaling in T1D prevention. We used the non-obese diabetic (NOD) mouse model of T1D, and generated mice with global 4E-BP2 deletion in the NOD background (Eif4epb2-/-). We assessed T1D development, glucose homeostasis, pancreas morphometry and immune responses in Eif4epb2-/- and littermate control mice. We found that Eif4epb2-/- male mice exhibited reduced diabetes incidence, which did not occur in female mice, and was associated with preserved β-cell mass, improved insulin secretion in vitro, and comparable insulitis. Characterization of T cell compartments showed decreased splenic CD8+ cytotoxic T cell proliferation and increased pancreatic regulatory T cell infiltration in Eif4epb2-/- mice, potentially due to increased proliferation and suppressive capacity. Adoptive transfer studies demonstrated that Eif4epb2-/- male lymphocytes were less diabetogenic than controls. Overall, activation of 4E-BP2/eIF4E by 4E-BP2 deletion protects against T1D, identifying 4E-BP2 as a potential therapy target.

  • Open Access

    Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T Cells

    by Melanie R. Shapiro, Leeana D. Peters, Matthew E Brown, Cecilia Cabello-Kindelan, Amanda L. Posgai, Allison L. Bayer, Todd M. Brusko

    IL-2 has been proposed to restore tolerance via regulatory T cell (Treg) expansion in autoimmunity, yet off-target effects necessitate identification of a combinatorial approach allowing for lower IL-2 dosing. We recently reported reduced levels of immunoregulatory insulin-like growth factor-1 (IGF1) during type 1 diabetes progression. Thus, we hypothesized that IGF1 would synergize with IL-2 to expand Tregs. We observed IGF1 receptor was elevated on murine memory and human naive Treg subsets. IL-2 and IGF1 promoted PI3K/Akt signaling in Tregs, inducing thymically-derived Treg expansion beyond either agent alone in NOD mice. Increased populations of murine Tregs of naive or memory, as well as CD5lo polyclonal or CD5hi likely self-reactive, status were also observed. Expansion was attributed to increased IL-2Rγ subunit expression on murine Tregs exposed to IL-2 and IGF1 as compared with IL-2 or IGF1 alone. Assessing translational capacity, incubation of naive human CD4+ T cells with IL-2 and IGF1 enhanced thymically-derived Treg proliferation in vitro, without the need for TCR ligation. We then demonstrated that IGF1 and IL-2 or IL-7, which is also IL-2Rγ-chain dependent, can be used to induce proliferation of genetically engineered naive human Tregs or T conventional cells, respectively. These data support the potential use of IGF1 in combination with common γ-chain cytokines to drive homeostatic T cell expansion, both in vitro and in vivo, for cellular therapeutics and ex vivo gene editing.


  • In vitro platform establishes antigen-specific CD8+ T cell cytotoxicity to encapsulated cells via indirect antigen recognition

    by Ying Li, Anthony W. Frei, Ethan Y. Yang, Irayme Labrada-Miravet, Chuqiao Sun, Yanan Rong, Magdalena M. Samojlik, Allison L. Bayer, Cherie L. Stabler


  • Open Access

    In VitroPlatform Establishes Antigen-Specific CD8+T Cell Cytotoxicity to Encapsulated Cells via Indirect Antigen Recognition

    by Ying Li, Anthony W. Frei, Ethan Y. Yang, Irayme Labrada-Miravet, Chuqiao Sun, Yanan Rong, Magdalena M. Samojlik, Allison L. Bayer, Cherie L. Stabler

    Cell replacement therapy has the potential to cure diseases caused by the absence or malfunction of specialized cells. A substantial impediment to the success of any non-autologous cellular transplant is the need for systemic immunosuppressive drugs to prevent host-mediated rejection of the foreign cells. Cellular encapsulation, i.e., the entrapment of cells within stable polymeric hydrogels, has been clinically explored to prevent host immune recognition and attack, but the efficacy of these encapsulated grafts is poor. While several studies have explored improvements in innate immune acceptance of these encapsulated cells, little attention has been paid to the roles of adaptive immune responses, specifically graft-targeting T cell activation, in graft destabilization. Herein, we established an efficient, single-antigenin vitroplatform capable of delineating direct and indirect host T cell recognition to microencapsulated cellular grafts and evaluating their consequential impacts. Using alginate as the model hydrogel, encapsulated membrane-bound ovalbumin (mOVA) stimulator cells were incubated with antigen-specific OTI lymphocytes and subsequent OVA-specific CD8+T cell activation and effector function were quantified. We established that alginate microencapsulation abrogates direct T cell activation by interrupting donor-host interaction; however, indirect T cell activation mediated by host antigen presenting cells (APCs) primed with shed donor antigens still occurs. These activated T cells imparted cytotoxicity on the encapsulated cells, likely via diffusion of cytotoxic solutes. Overall, this platform delivers unique mechanistic insight into the impacts of hydrogel encapsulation on host adaptive immune responses, as well as a tool for the efficient immune screening on new encapsulation methods and/or synergistic immunomodulatory agents.

  • Open Access

    Immunomodulation Followed by Antigen-Specific Treg Infusion Controls Islet Autoimmunity

    by Cecilia Cabello-Kindelan, Shane Mackey, Alexander Sands, Jennifer Rodriguez, Claudia Vazquez, Alberto Pugliese, Allison L. Bayer

    Optimal immune-based therapies for type 1 diabetes (T1D) should restore self-tolerance without inducing chronic immunosuppression. CD4+Foxp3+ regulatory T cells (Tregs) are a key cell population capable of facilitating durable immune tolerance. However, clinical trials with expanded Tregs in T1D and solid-organ transplant recipients are limited by poor Treg engraftment without host manipulation. We showed that Treg engraftment and therapeutic benefit in nonautoimmune models required ablative host conditioning. Here, we evaluated Treg engraftment and therapeutic efficacy in the nonobese diabetic (NOD) mouse model of autoimmune diabetes using nonablative, combinatorial regimens involving the anti-CD3 (αCD3), cyclophosphamide (CyP), and IAC (IL-2/JES6–1) antibody complex. We demonstrate that αCD3 alone induced substantial T-cell depletion, impacting both conventional T cells (Tconv) and Tregs, subsequently followed by more rapid rebound of Tregs. Despite robust depletion of host Tconv and host Tregs, donor Tregs failed to engraft even with interleukin-2 (IL-2) support. A single dose of CyP after αCD3 depleted rebounding host Tregs and resulted in a 43-fold increase in donor Treg engraftment, yet polyclonal donor Tregs failed to reverse diabetes. However, infusion of autoantigen-specific Tregs after αCD3 alone resulted in robust Treg engraftment within the islets and induced remission in all mice. This novel combinatorial therapy promotes engraftment of autoantigen-specific donor Tregs and controls islet autoimmunity without long-term immunosuppression.


  • CCL21 Expression in β-Cells Induces Antigen-Expressing Stromal Cell Networks in the Pancreas and Prevents Autoimmune Diabetes in Mice

    by Freddy E. Gonzalez Badillo, Flavia Zisi Tegou, Maria M. Abreu, Riccardo Masina, Divya Sha, Mejdi Najjar, Shane H. Wright, Allison L. Bayer, Éva Korpos, Alberto Pugliese, et al.

    Tumors induce tolerance toward their antigens by producing the chemokine CCL21, leading to the formation of tertiary lymphoid organs (TLOs). Ins2-CCL21 transgenic, nonobese diabetic (NOD) mice express CCL21 in pancreatic β-cells and do not develop autoimmune diabetes. We investigated by which mechanisms CCL21 expression prevented diabetes. Ins2-CCL21 mice develop TLOs by 4 weeks of age, consisting of naive CD4+ T cells compartmentalized within networks of CD45−gp38+CD31− fibroblastic reticular cell (FRC)–like cells. Importantly, 12-week-old Ins2-CCL21 TLOs contained FRC-like cells with higher contractility, regulatory, and anti-inflammatory properties and enhanced expression of β-cell autoantigens compared with nontransgenic NOD TLOs found in inflamed islets. Consistently, transgenic mice harbored fewer autoreactive T cells and a higher proportion of regulatory T cells in the islets. Using adoptive transfer and islet transplantation models, we demonstrate that TLO formation in Ins2-CCL21 transgenic islets is critical for the regulation of autoimmunity, and although the effect is systemic, the induction is mediated locally likely by lymphocyte trafficking through TLOs. Overall, our findings suggest that CCL21 promotes TLOs that differ from inflammatory TLOs found in type 1 diabetic islets in that they resemble lymph nodes, contain FRC-like cells expressing β-cell autoantigens, and are able to induce systemic and antigen-specific tolerance leading to diabetes prevention.


  • Open Access

    Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol

    by Vita Manzoli, Chiara Villa, Allison L. Bayer, Laura C. Morales, R. Damaris Molano, Yvan Torrente, Camillo Ricordi, Jeffrey A. Hubbell, Alice A. Tomei